The short version is this: retatrutide acts at the GLP-1 receptor, but it is not a GLP-3, because there is no such thing as a GLP-3. The most accurate label for the molecule is a triple receptor agonist, since it activates the GLP-1 receptor along with the GIP receptor and the glucagon receptor. So if the choice is framed as GLP-1 or GLP-3, the answer leans toward GLP-1, with the important caveat that even that undersells what the molecule does.
This article works through why. For the molecule’s identity, development code, and specifications, see the companion guide on what retatrutide is. Retatrutide research peptides are supplied for laboratory research use only, and the discussion below is about classification and naming, not approval or any direction for use.
The short answer, in plain terms
Retatrutide is, in part, a GLP-1 receptor agonist. That means one of the three receptors it binds and activates is the receptor for glucagon-like peptide-1, usually written GLP-1. On that count, it belongs to the broad family of compounds that act on the GLP-1 receptor, the same family that includes single-target peptides.
It is not a GLP-3, though, and the reason is simple: GLP-3 is not a real hormone, receptor, or drug class. The term is an informal nickname that some people have applied to retatrutide because the molecule engages three receptors, but it is not used by scientists, clinicians, or regulators, and it does not name anything that exists in the body.
The label that researchers actually use is triple-hormone receptor agonist, or triple agonist. It captures the real point, which is that a single peptide acts on three separate receptors at once, rather than implying a third numbered member of the GLP series that was never there.
Where the GLP-3 nickname comes from
The nickname is easy to understand even though it is wrong. Single GLP-1 agonists came first, then dual agonists that add a second receptor, and retatrutide adds a third. Counting upward from that progression, three receptors becomes GLP-3 in casual shorthand, and it reads like the natural next number in a series.
The problem is that the number in GLP-1 does not count receptors or hormones in the first place. The 1 is part of the name of the hormone itself, glucagon-like peptide-1, in the same way that GLP-2 names a different hormone. Neither number refers to how many targets a drug engages. Extending the pattern to GLP-3 confuses the name of a hormone with the number of receptors a molecule hits.
Because of that mismatch, GLP-3 stays an informal, marketing-style label rather than a scientific one. It appears in some product listings and popular articles, but it will not appear in the peer-reviewed literature or in a regulator’s description of the compound. When accuracy matters, triple agonist is the term to use.
The real GLP family: GLP-1 and GLP-2
To see why there is no GLP-3, it helps to know where GLP-1 comes from. GLP-1 and GLP-2 are both derived from a single precursor protein called proglucagon. Depending on the tissue and the enzymes doing the cutting, proglucagon is processed into several different peptides.
In the intestine and brain, that processing yields glucagon-like peptide-1 and glucagon-like peptide-2, along with other named fragments such as oxyntomodulin and glicentin. In the pancreas, the same precursor is cut differently to release glucagon. GLP-1 and GLP-2 are the two numbered glucagon-like peptides in that family, and the numbering stops at two because those are the peptides the biology actually produces.
GLP-2 is a real hormone, but a different one, and it is not a second-generation GLP-1 drug. It acts mainly on the intestine, where it supports the growth and function of the gut lining. A peer-reviewed comparison of the two peptides is available from the National Library of Medicine. Adding a receptor target to a molecule, as retatrutide does, does not create a new GLP-3 hormone.
What the GLP-1 part of retatrutide refers to
When retatrutide is described as acting on GLP-1, that means the GLP-1 receptor, one of its three targets. The GLP-1 receptor is a G-protein-coupled receptor, and it is widely distributed in the body, appearing in the pancreas, the brain, the heart, the kidney, and the gastrointestinal tract.
At the receptor level, GLP-1 receptor activation drives glucose-dependent insulin secretion, meaning insulin release is amplified when glucose is elevated. It also slows the rate at which the stomach empties and lowers hunger signaling in the brain. These are the receptor-level actions associated with the GLP-1 arm, and they are the same actions that single GLP-1 agonists rely on.
In retatrutide, this GLP-1 activity is the anchor, but it is only one of three. The molecule pairs it with activity at the GIP receptor and the glucagon receptor, which is why calling the whole compound a GLP-1 agonist is accurate only as far as it goes.
So is retatrutide simply a GLP-1 agonist?
Calling retatrutide a GLP-1 agonist is not wrong, but it is incomplete. Semaglutide is a single GLP-1 agonist, and it acts on that one receptor. Tirzepatide is a dual agonist that adds the GIP receptor, and the field calls it a GIP and GLP-1 receptor agonist rather than a GLP-2. Retatrutide goes one receptor further.
| Compound | Receptor targets | Class |
|---|---|---|
| Semaglutide | GLP-1 receptor | Single agonist |
| Tirzepatide | GLP-1 and GIP receptors | Dual agonist |
| Retatrutide | GLP-1, GIP, and glucagon receptors | Triple agonist |
By adding glucagon-receptor activity on top of GLP-1 and GIP, retatrutide becomes a triple agonist. That is the feature that distinguishes it from the single and dual agonists that came before, and it is the reason a simple GLP-1 label undersells it. For the receptor-by-receptor detail, see the companion article on the retatrutide mechanism of action.
So the honest answer to the title question is layered. Retatrutide acts at the GLP-1 receptor, so in that sense it is a GLP-1 agonist. It is not a GLP-3, because no such class exists. And the fullest description is that it is a triple GLP-1, GIP, and glucagon receptor agonist.
Why the naming matters for research
For a research setting, precise naming is more than a pedantic point. Describing a compound by the receptors it actually targets, GLP-1, GIP, and glucagon, tells you what it is expected to do in an assay far better than an informal label like GLP-3 does. The nickname carries no scientific information about the molecule.
The GLP-3 label also shows up in commerce, where some product listings use it as shorthand for retatrutide. That is a marketing convenience rather than a specification. When you need the real detail on a given material, the receptor targets, the identity, and the reported purity come from the product record and the Certificate of Analysis for the specific lot, not from a nickname.
Using the accurate term keeps research notes, product records, and literature searches aligned. It also avoids the confusion of hunting for a GLP-3 hormone or receptor that was never part of the biology in the first place.
How the classification was established
The classification rests on two well-established bodies of science. The identity of retatrutide as a triple GLP-1, GIP, and glucagon receptor agonist comes from the primary pharmacology, including the discovery paper by Coskun and colleagues in Cell Metabolism (2022) and the phase 2 study by Jastreboff and colleagues in the New England Journal of Medicine (2023).
The reason there is no GLP-3 comes from the biology of the proglucagon family, where GLP-1 and GLP-2 are the two numbered glucagon-like peptides and no third one exists. Readers who want the primary material can consult the phase 2 retatrutide trial in the New England Journal of Medicine and the proglucagon-peptide review from the National Library of Medicine.
Between the two, the picture is consistent. Retatrutide is a GLP-1 receptor agonist as one of three activities, it is a triple agonist overall, and GLP-3 is a nickname rather than a scientific category.
Research use only
This article is a classification and naming reference for retatrutide research peptides. It explains how the compound is described in the scientific literature and why the GLP-3 label is informal. It is not a statement of regulatory approval, medical availability, or any instruction for use.
All products are supplied for research and development use only. They are not for human or veterinary use, and they are not intended to diagnose, treat, cure, or prevent any disease. Anyone using this material is responsible for handling it in line with institutional requirements and applicable law.